NoRD Bio’s team of experts in the assessment of tumor heterogeneity and evolution has launched a program to aid pharma and biotech companies in cancer drug development.
NoRD Bio, Inc., an innovative company at the forefront of genomic and transcriptomic analysis, is proud to announce that it has been awarded a prestigious SBIR grant.
